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ABSTRACT 
 Chimeric antigen receptor (CAR) T-cell therapy is an emerging cancer treatment option 
throughout the world. This approach to cancer treatment uses a patient’s own immune cells 
and engineers them to directly target and kill cancer that has been evading their immune 
system. There has been much success when using CAR T-cell therapy in hematological 
malignancies due to the almost universal expression of the CD19 antigen. Though this success 
has not translated into success with solid tumors, there has been extensive research to improve 
the results. Solid tumors pose as a more difficult target due to their variable expression of 
target antigens, difficulty to penetrate, and hostile microenvironment. These challenges have 
been investigated and tested to improve CAR T-cell therapy success in the future. 
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INTRODUCTION 
Cancer, second only to heart attack, is a leading cause of death throughout the world. 
Although modern technology has improved therapies such as surgery, radiation, and 
chemotherapy, the general cancer survival rate has not risen significantly. Immunotherapy is 
one area of cancer treatment research that has shown promising results. Adoptive T-cell 
therapy (ACT) is one approach where a patient’s own lymphocytes are removed and engineered 
to recognize tumor antigens through T-cell receptors (TCRs) or chimeric antigen receptors 
(CARs). CAR-T cell therapy has proved successful and has multiple benefits over other 
treatments such as the aforementioned TCR-modified T-cells. These benefits include 
recognizing antigens independently of the major histocompatibility complex (MHC), ability to 
target proteins, carbohydrates, and glycolipids expressed by tumor cells, and the ability to 
modify the CARs with co-stimulatory molecules to augment cytotoxicity and prolong lifespan in 
vivo (Muhammad, Niaz, et al., 2017). 
 
CAR T-CELL ANATOMY 
The basic anatomy of a CAR includes three sections: an extracellular domain, 
transmembrane domain, and an intracellular signaling domain. The extracellular domain is an 
antigen-binding domain composed of a single-chain variable fragment (scFv) of a tumor 
antigen-reactive antibody. This scFv, consisting of the variable portions of heavy and light 
chains from the antibody, are joined to each other by a peptide linker and fused to the 
transmembrane domain by a hinge domain (Nair, Ranjit, and Sattva S Neelapu, 2018). The 
transmembrane domain is comprised of a hydrophobic alpha helix traversing the cellular 
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membrane to be linked to the intracellular signaling domain within the cytosol of the cell. This 
intracellular signaling domain is the functional end of the CAR. In the first generation of CARs, 
the intracellular signaling domain was a single CD3 chain. Based off the amount of signaling 
molecules on the intracellular signaling domain, there are currently four generations of CARs 
(Zhang, Cheng, et al., 2017). 
The first generation of CARs contained the single CD3 chain for the intracellular 
signaling domain. This assembly did not perform well in vivo due to the inability to produce 
sufficient interleukin-2 (IL-2) and did not yield results in studies due to poor proliferation, short 
lifespan in vivo, and insufficient cytokine products (Zhang, Cheng, et al., 2017). It was concluded 
that CARs with only the CD3 chain could not adequately activate the CAR T-cells (Zhang, 
Cheng, et al., 2017). 
The second generation of CARs were produced by complementing the CD3 chain with 
co-stimulatory molecules such as CD28 or CD137 (4-1BB and CD134 (OX40)). This addition 
enhanced the proliferation, cytotoxicity, and extended the lifespan of the CAR T-cells in vivo. 
The third generation of CARs were produced by fusing multiple signaling domains 
(Figure 1). These two co-stimulatory molecules derived from p56 Ick + CD28, OX40 + CD28, or 4-
1BB+CD28 in addition to the CD3 chain. This assembly showed to increase the potency with 
higher levels of cytokine production (Zhang, Cheng, et al., 2017). 
The fourth generation CAR was produced by combining the second generation CARs 
with a cytokine expression cassette (Figure 1). These are known as T-cell redirected for 
universal cytokine-mediated killing (TRUCKs). These CARs have the ability to increase the 
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activation of T-cells and attract immune cells to eliminate antigen-negative tumor cells by 
releasing anti-tumor cytokines (Yan Ll, and Liu Bn., 2018). 
 
Figure 1. The evolution of chimeric antigen receptors (CARs). This shows the progression from the first generation 
to the fourth. The CD3 chain is conserved through all generations (Zhang, Cheng, et al., 2017). 
 
CURRENT SUCCESS 
Thus far, Car T-cell therapy has shown great success in treating hematological 
malignancies. This is due to the expression of CD19 by almost all B-cell malignancies such as 
chronic lymphocytic leukemia (CLL), B-cell acute lymphoblastic leukemia (B-ALL), and Non-
Hodgkin Lymphomas (NHLs) (Muhammad, Niaz, et al., 2017). The first successful treatment of 
CLL by CAR T-cell therapy used CAR T-cells that targeted the B-cell antigen, CD19 (Kalos, 
Michael, et al., 2011). Although CAR T-cell therapy has been very successful in treating 
hematological malignancies, the same success has not been provided in the treatment of solid 
tumors. There may be numerous unknown obstacles accounting for the poor success, but the 
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known challenges of solid tumors are finding, infiltrating, and surviving within the solid tumor 
(Marina Martinez, and Edmund Kyung Moon., 2019). 
 
FINDING ANTIGENS 
The main difference with solid tumors versus hematological malignancies is that solid 
tumors do not universally express a targetable antigen such as the CD19 antigen in 
hematological malignancies. This makes it difficult for CAR T-cells to differentiate between 
normal tissues and tumor cells. The ideal target for solid tumors should be overexpressed on 
tumor cells and show none or very little expression on normal, healthy tissues in the cancer 
patient. Some tumor associated antigens (TAAs) that are being researched are mesothelin 
(MSLN), HER2, EGFR/EGFRvIII, GD2, CEA, IL13R2, MUC1, FAP, PSMA, and PSCA (Li, Jian, et al., 
2018) 
Unlike hematological malignancies, solid tumors do not universally express a TAA that is 
not also expressed on normal tissues. Therefore, a major concern with CAR T-cell therapy for 
solid tumors is off-target cytotoxicity. An example of this is in a CAR T-cell therapy for 
neuroblastoma using a high affinity anti-GD2 CAR. This construct caused lethal central nervous 
system toxicity through excessive CAR T-cell infiltration and proliferation and resulted in lethal 
encephalitis (Richman, Sarah A, et al., 2018). This shows that selecting the correct antigen is 
essential because off-target cytotoxicity on normal tissues may have unfavorable 
consequences. Regulating the binding affinity of CAR T-cells to antigens may be a way to avoid 
toxicity in normal tissues. In a study of tuning the affinity of CAR T-cells to ICAM-1 in thyroid 
tumors, the safety and efficacy was compared between CAR T-cells with a one million-fold 
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difference in binding-affinity. This difference was from low nanomolar to high micromolar 
affinity to the ICAM-1 antigen. The results of this study concluded that the micromolar binding-
affinity performed better in safety and efficacy when compared to the nanomolar. At the high 
micromolar affinity, CAR T-cells produced death of host by on/off-target toxicity as well as high 
levels of cytokine release (Spencer Park, et al., 2017). These results show that a higher binding 
affinity is not always better and may cause unwanted toxicity to the host. Another solution to 
the problem of off-target toxicity is to insert a safety switch that can turn CAR T-cells on or off. 
One such switch is an inducible Capsase 9 (iCasp9) gene that can induce apoptosis of CAR T-cells 
that may cause toxicity to normal tissue. Administration of a small molecule dimerizer drug, 
AP1903, causes mass apoptosis of the activated cells expressing the transgene (Tessa E. gargett, 
and Michael E. brown, 2014). Opposite to the inducible iCasp9 off switch, there is an on switch 
that is capable of introducing the CAR T-cells in a gradual fashion. The design of the on switch 
requires both binding of antigen and a small molecule drug for dimerization and activation in a 
split-receptor approach. This assembly allows for exogenous control over CAR T-cell antitumor 
processes such as proliferation, cytokine production, and cytotoxicity (Wu, Chia-Yung, et al., 
2015). Another inducible on switch for CAR T-cells has been found to be an ultrasound-based 
mechanogenetics system. This system has the ability to noninvasively control the genetics of 
cells with high frequency ultrasound. For this to work, the mechanically sensitive Piezo1 ion 
channel linked to transcriptional activities was engineered into Jurkat T-cells. Application of 
ultrasound to the T-cells induced the expression of CARs. This method allows for precise 
activation of CAR T-cells to protects against off-target toxicity (Pan, Yijia, et al., 2018). 
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INFILTRATION 
Even if a good solid tumor antigen is found, the next obstacle a CAR T-cell encounters is 
infiltrating the solid tumor from the bloodstream. This homing from the bloodstream to tissues 
requires adhesive interactions between the CAR T-cells and the wall of the blood vessel. The 
stages of these interactions can be grouped into rolling, activating-induced arrest, and 
movement into the tissue (Ager, Ann, et al., 2016). The ability of CAR T-cells to home to a solid 
tumor is controlled by their expression of chemokine receptors matching the chemokines 
within the solid tumor. Chemokines expressed by the tumor cells may not match the 
chemokine receptor of the CAR T-cells. This limits recruitment into the solid tumor (Harlin, 
Helena, et al., 2009).  
Chemokines provide a chemotactic gradient for immune cells to follow to produce an 
immune response. There has been a study that used CXCR3 ligands (CXCL9, CXCL10, and 
CXCL11) and transfected mice with them using a recombinant adenovirus-based vaccination. It 
was found that the strongest effect on CD8+ T cells was produced when CXCL11 was 
administered with the vaccine. These results were confirmed with a therapeutic tumor mouse 
model. This showed that delivery of CXCL11 into a tumor may provide increased CAR T cell 
infiltration and toxicity to solid tumors (Namkoong, Hong, et al., 2014).  
There may be a way to evade the barriers of CAR T-cells infiltrating into solid tumors. 
One study of HER2-CAR T-cells against HER2+ metastases of the brain showed that injecting the 
CAR T-cells intratumorally produced complete tumor regression. This study was conducted 
using a xenograft mouse model. When treated with intravenously injected HER2-CAR T-cells at 
10-fold higher doses, the model only showed partial antitumor responses (Priceman, Saul J, et 
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al., 2018). The results of this study show that intratumoral delivery of CAR T-cells against solid 
tumors may be a way to increase efficacy, gain complete tumor regression, and avoid off-target 
toxicities. 
 
SURVIVAL IN THE TUMOR MICROENVIRONMENT 
 If a CAR T-cell is able to cross a solid tumor’s barriers and find itself inside the tumor, 
there are more challenges to overcome. The tumor microenvironment (TME) is significantly 
suppressive to immune cells. The TME is composed of non-neoplastic cells that provide support 
for the neoplasm of the tumor. Within the TME, there are multiple cells and secretory factors 
that suppress the function of CAR T-cell. These include T-regulatory Lymphocytes (Tregs), 
myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), tumor 
associated neutrophils, and stromal fibroblasts. Tregs have the ability to uptake IL-2 to blunt 
the effect of CAR T-cells that are present. Both Tregs and TAMs secrete IL-10, a suppressive 
cytokine that aids in the proliferation of tumor cells (Gowrishankar, Kavitha, et al., 2018). 
MDSCs are able to suppress anti-tumor functions by stimulating Tregs to produce reactive 
oxygen species to suppress the response of T-cells by oxidative stress. In the inflammatory 
environment of a solid tumor, it upregulates the expression of the programmed cell death 
ligand ½ (PD-L1/2). This pathway is used by the tumor to induce exhaustion of CAR T-cells. This 
exhaustion results in decreased proliferation and production of cytokines like IL-2, TNF-, and 
IFN-. When a T-cell is exhausted, it expresses elevated levels of receptors that can bind PD-L1, 
which results in suppression of their anti-tumor activities to allow survival of the tumor 
Morgan, Michael A., and Schambach, Axel., 2018). 
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The stromal compartment of the solid tumor provides protection and serves as a 
physical barrier to inhibit infiltration by CAR T-cells. This compartment is comprised of non-
malignant fibroblasts and mesenchymal cells surrounded by blood vessels, immune cells, 
matrix, and inflammatory mediators. The fibroblasts have the ability to convert to cancer-
associated fibroblasts (CAFs) and express fibroblast activating protein (FAP). The expression of 
FAP by CAFs can bring in endothelial cells for increased vasculature, cause collagen crosslinking, 
and matrix degradation. These, together, promote the development of the tumor. The collagen 
crosslinking introduces complexity to the outside of the tumor and makes it more difficult for 
CAR T-cells to infiltrate (Gowrishankar, Kavitha, et al., 2018). There has been a study conducted 
on the results of targeting FAP by FAP-targeted CAR T-cells. The results showed that FAP+ 
cancer-associated stromal cells are necessary for the progression of a solid tumor. Using the 
FAP-CAR T-cells decreased vasculature and inhibited growth of tumors (Lo, Albert, et al., 2015). 
These results are promising for the future therapeutic advantages of controlling tumor growth 
in an immune-dependent and -independent fashion. 
Solid tumors have another blockade for infiltrating CAR T-cells. The low oxygen (hypoxic) 
environment within the TME is due to abated blood flow, abnormal vascularization, and the 
production of hydrogen peroxide. Reactive oxygen species (ROS), such as hydrogen peroxide, 
impair the anti-tumor activities and put stress on CAR T-cells. One way to combat oxidative 
stress from ROS is to use CARs that are able to express the enzyme Catalase (Gowrishankar, 
Kavitha, et al., 2018). Catalase metabolizes hydrogen peroxide into water and oxygen. A way to 
protect CAR T-cells from oxidative stress within the TME was conducted by engineering T-cells 
with a bicistronic vector to express catalase with the CAR co-expressing catalase (CAR-CAT). 
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These CAR-CAR T-cells proved to reduce the amount of oxidative stress and even exhibited a 
bystander effect. This bystander effect protected NK cells from oxidative stress and allowed 
them to exert anti-tumor functions (Ligtenberg, Maarten A, et al., 2016). 
 
FUTURE DIRECTIONS 
CAR T-cell therapy for solid tumors has shown promising results over the last few years. But 
there is still much room for improvement in the areas of efficacy and safety. The gene-editing 
power of CRISPR/Cas9 could be the future for allowing CAR T-cells to find, enter, and survive 
within solid tumors. One application for CRISPR/Cas9 is the production of off-the-shelf CAR T-
cells. Currently, CAR T-cell formation requires the use of a patient’s own lymphocytes. This 
involves knocking out the TRAC and B2M genes through CRISPR/Cas9 to produce universal CAR 
T-cells made from allogenic cells. Also, CRISPR/Cas9 has been utilized to knock-out the PD-1 
gene in T-cells. This allows CAR T-cells to pass immune checkpoints on solid tumors and 
improves cytotoxicity (Qianqian Gao, et al., 2019). There is an example of this approach being 
used in a phase I clinical trial investigating CD19-specific CAR T-cells with PD-1 knockout 
(NCT03298828). 
 
CONCLUSION 
In conclusion, CAR T-cell therapy has come a long way but still has much potential to keep 
progressing into the cancer therapy of the future. The success seen in hematological 
malignancies has not yet transferred to solid tumors. There are still current efficacy and safety 
issues that present as major hurdles to overcome before CAR T-cell therapy becomes the 
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mainstream treatment option for solid tumors. There have been many advances in the areas of 
target antigens, controlling off-target toxicity, improving infiltration, and surviving within solid 
tumors. With the problems presented, CRISPR/Cas9 may be the solution to providing cheap, 
safe, and universally available CAR T-cells to those in need. 
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